Dosimetry analysis of two new design 103 Pd interstitial brachytherapy sources

Q4 Medicine

International Journal of Low Radiation Pub Date : 2011-01-01 DOI:10.1504/IJLR.2011.047177

P. Saidi, M. Sadeghi, A. Shirazi, S. Mahdavi, M. Mirzaii

{"title":"Dosimetry analysis of two new design 103 Pd interstitial brachytherapy sources","authors":"P. Saidi, M. Sadeghi, A. Shirazi, S. Mahdavi, M. Mirzaii","doi":"10.1504/IJLR.2011.047177","DOIUrl":null,"url":null,"abstract":"With increased demand for low 103 Pd (palladium) seed sources, to treat prostate and eye cancers, new sources have been designed and introduced. This paper presents the two new palladium brachytherapy sources, IR03- 103 Pd and IR04- 103 Pd that have been developed at Agricultural, Medical & Industrial Research School . The dosimetric parameters, such as the dose rate constant Λ , the radial dose function g ( r ) and the anisotropy function F ( r , θ ), around the sources have been characterised using Version 5 Monte Carlo radiation transport code in accordance with the update AAPM Task Group No. 43 Report (TG-43U1). The results indicated the dose rate constant of 0.689 ± 0.02 and 0.667 ± 0.02 cGy h -1 U -1 for the IR03- 103 Pd and IR04- 103 Pd sources, respectively, which are in acceptable agreement with other commercial seeds. The calculated results were compared with published results for those of other source manufacturers. However, they show an acceptable dose distribution, using for clinical applications is pending experimental dosimetry.","PeriodicalId":14141,"journal":{"name":"International Journal of Low Radiation","volume":"8 1","pages":"363"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1504/IJLR.2011.047177","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Low Radiation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1504/IJLR.2011.047177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

With increased demand for low 103 Pd (palladium) seed sources, to treat prostate and eye cancers, new sources have been designed and introduced. This paper presents the two new palladium brachytherapy sources, IR03- 103 Pd and IR04- 103 Pd that have been developed at Agricultural, Medical & Industrial Research School . The dosimetric parameters, such as the dose rate constant Λ , the radial dose function g ( r ) and the anisotropy function F ( r , θ ), around the sources have been characterised using Version 5 Monte Carlo radiation transport code in accordance with the update AAPM Task Group No. 43 Report (TG-43U1). The results indicated the dose rate constant of 0.689 ± 0.02 and 0.667 ± 0.02 cGy h -1 U -1 for the IR03- 103 Pd and IR04- 103 Pd sources, respectively, which are in acceptable agreement with other commercial seeds. The calculated results were compared with published results for those of other source manufacturers. However, they show an acceptable dose distribution, using for clinical applications is pending experimental dosimetry.

查看原文本刊更多论文

两种新设计的103 Pd间质性近距离放射治疗源的剂量学分析

随着对低103 Pd(钯)种子源的需求增加，用于治疗前列腺癌和眼癌，新的来源已被设计和引入。本文介绍了农业、医学和工业研究学院开发的两种新型钯近距离治疗源IR03- 103pd和IR04- 103pd。辐射源周围的剂量学参数，如剂量率常数Λ、径向剂量函数g (r)和各向异性函数F (r， θ)，已根据最新的AAPM工作组第43号报告(TG-43U1)，使用第5版蒙特卡罗辐射输运代码进行了表征。结果表明，IR03- 103 Pd和IR04- 103 Pd源的剂量率常数分别为0.689±0.02和0.667±0.02 cGy h -1 U -1，与其他商品种子的剂量率常数基本一致。计算结果与公布的其他来源制造商的结果进行了比较。然而，它们显示出可接受的剂量分布，用于临床应用尚待实验剂量测定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Low Radiation Environmental Science-Health, Toxicology and Mutagenesis

自引率

0.00%

发文量

期刊介绍： The IJLR is a peer-reviewed journal dedicated to the publication of research articles, review papers and technical notes in all domains related to low-dose radiation, among which are the biological and health effects in humans and the biota, in vitro and in vivo research on low radiation effects, regulatory and policy aspects, risk estimation and public perception.